Form 4: BioMarin Pharmaceutical Inc. Director Bienaime Reports Acquisition and Disposal of Shares

Director Jean Jacques Bienaime reports acquisition of shares through Restricted Stock Units (RSUs) and disposal of shares via open market sale.

Summary

• On February 27, 2024, Jean Jacques Bienaime, a director at BioMarin Pharmaceutical Inc., acquired shares of common stock through the earning of Restricted Stock Units (RSUs).
• These RSUs are convertible into common stock on a 1:1 basis.
• The RSUs were earned based on performance metrics including relative total shareholder return, achievement of strategic goals, and non-GAAP income over the periods spanning 2021 through 2023.
• Specifically, 82,700 RSUs were earned based on total shareholder return, 35,975 RSUs were earned based on strategic goals, and 24,926 RSUs were earned based on non-GAAP income.
• Also on February 27, 2024, Bienaime disposed of 1,000 shares of common stock at a price of $90.35 per share.
• Following these transactions, Bienaime directly owns 562,203 shares of common stock.
• Bienaime also indirectly owns 247,333 shares through a family trust and 200 shares as UTMA custodian for two children.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports transactions related to executive compensation. The acquisition of RSUs suggests achievement of performance goals, while the sale of shares is a routine transaction.

Positives

• The acquisition of RSUs indicates that performance goals related to shareholder return, strategic goals, and non-GAAP income were met, which could be viewed positively.

Negatives

• The sale of 1,000 shares, while a small portion of overall holdings, could be interpreted negatively if viewed as a lack of confidence, although it could also be for personal financial management.

Risks

• The vesting of the RSUs is contingent on continued service through March 15, 2024, and could be impacted by unforeseen events.
• Future performance may not meet the same metrics as the 2021-2023 period, affecting future RSU earnings.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of RSUs on March 15, 2024, is contingent on continued service.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry. It reflects the company's performance-based compensation structure.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded pharmaceutical companies such as Amgen (AMGN), Gilead Sciences (GILD), and Vertex Pharmaceuticals (VRTX).
• These companies often use metrics like total shareholder return, revenue growth, and pipeline milestones to determine equity awards.
• The specific formulas and vesting schedules vary, but the general principle of aligning executive compensation with company performance is consistent.

Stakeholder Impact

• The acquisition of RSUs based on performance metrics aligns management's interests with those of shareholders.
• The vesting of RSUs incentivizes continued service and commitment to the company's goals.

Next Steps

• Vesting of RSUs on March 15, 2024, contingent on continued service.

Key Dates